Central & Peripheral Nervous System: 5-HT₃ receptor antagonists

References

• GADDUM JH, PICARELLI ZP: Two kinds of tryptamine receptor. Br. J. Pharmacol. (1957) 12: 323–328.
   PubMed Web of Science ®Google Scholar
• ZIFA E, FILLION G: 5-Hydroxylryptamine Receptors.Pharmacol. Rev. (1992) 44(3): 401–458. Extensive review of 5-HT receptors.
   Google Scholar
• HUMPHREY PPA, HARTIG P, HOYER D: A proposed new nomenclature for 5-HT receptors. Trends in Pharm. Sci.(1993) 14: 233–236. Important review of the new receptors.
   Google Scholar
• SANGER GJ, NELSON GR: Selective and functional 5-hy-droxytryptamine receptor antagonism by brl 43694(Granisetron). Eur. J. Pharmacol. (1989) 159: 113–124. First full publication on granisetron.
   Google Scholar
• BUTLER A, HILL JM, IRELAND SJ, JORDAN CC, MYERS MB:Pharmacological Properties of GR 3032F, a novel an-tagonist as 5-HT3 receptors. Br. J. Pharmacol. (1988) 94: 387–412. First full publication on ondansetron.
   Google Scholar
• RICHARDSON BP, ENGEL G, DONATSCH P, STADLER PA:Identification of serotonin m-receptor subtypes andtheir specific blockade by a new class of drugs. Nature (1985) 316: 126–131. First full report on tropisetron.
   Google Scholar
• ANDREWS PL, BHANDARI P, DAVEY PT, BINGHAM S, MARR HE, BLOWER PE: Are all 5-HT3 receptor antago-nists the same? Eur. J. Cancer (1992) 28A: Suppl 1:S2–6.
   Google Scholar
• SAGRADA A, TURCONI M, BONALI P, SCHIANTRELLI P, MICHELETTI R, MONTAGNA E, NICOLA M, ALGATE DR, RIMOLDI EM, DONETTI A: Antiemetic activity of the new 5-HT3 receptor antagonist, DAU6215, in animal models of cancer chemotherapy and radiation. Cancer Chem other. Pharmacol. (1991) 28(6): 470–474.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ AG, PUIG J, BELETA J, DOMENECH T, BOU J, BERGA P, GRISTWOOD RW, ROBERTS DA: Pancoprkle, a potent and long acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur,J. Pharmacol. (1992) 222: 257–264.
   PubMed Web of Science ®Google Scholar
• JOSS RA, DOTT CS: Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group. Eur. J. Cancer. (1993) 29A: Suppl 1: S22–9.
   PubMedGoogle Scholar
• MARTIN M, ROSELL R, GUILLEM V, DIAZ-RUBIO E, MORENO I, SORIANO V, FERNANDEZ A, PEREZ A: LAS30451: a novel 5-HT3 antagonist. Eur.J. Cancer. (1993) 29A: Suppl 1: S33–4.
   Google Scholar
• SEYNAEVE C, DE MULDER PH, LANE-ALTMAN E, VAN LISSUM PA, VRWEJI J: The 5-3HT3 receptor antagonist, ondansetron, re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. Clin. Oncol. R. Coll. Radiol. (1991) 3: 199–203.
   PubMedGoogle Scholar
• SORBE B, BERGLIND AM, DE-BRUIJN K: Tropisetron, a HT3 receptor antagonist, in the prevention of irradia-tion-induced nausea, vomiting and diarrhoea. Eur. J. Gynaecol. Oncol. (1992) 13: 382–389.
   PubMedGoogle Scholar
• FREEMAN AJ, CUNNINGHAM KT, TYERS MB: Selectivity of 5-HT3 receptor antagonists, and anti-emetic mecha-nisms of action. Anticancer Drugs 1992 3: 79–85.
   PubMed Web of Science ®Google Scholar
• BARNES JM, COSTALL B, KELLY ME, NAYLOR RJ, ONAIVI ES, TOMKINS DM, TYERS MB: 1989). GR38032F improves performance in a mouse habituation test, and inhibits cholinergic-linked deficits. Br. J. Pharmacol. (1989) 98: 693P.
   Google Scholar
• COSTALL B, DOMENEY AM, GERRARD PA, JONES DNC,NAYLOR RJ, TYERS MB: Effects of GR38032F on perform-ance of common marmosets (Callitbrix Jaccbus) in an object discrimination reversal task. Br. J. Pharmacol. (1989) 98: 637P.
   PubMedGoogle Scholar
• CROOK TH: Effects of ondansetron in age-associated memory impairment. In: Satellite Symposium, (The role of ondansetron, a novel 5-HT3 receptor antagonist, in the treat-ment of psychiatric disorders (1991). 5th World Congress of Biological Psychiatry, Florence.
   Google Scholar
• COSTALL B, DOMENEY AM, NAYLOR RJ, TYERS MB: Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br. J. Pharmacol. (1987) 92: 881–894.
   PubMed Web of Science ®Google Scholar
• MORAN PM and MOSER PC: MDL 73,147EF, a 5-11T3 receptor antagonist, facilitates latent inhibition in the rat. Pharmacol. Biochetn. Behav. (1992) 42: 519–522.
   PubMed Web of Science ®Google Scholar
• SILVERSTONE PH, OLDHAM D, JOHNSON B, COWEN PJ: Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. Int. Clin. Pharmacol. (1992) 7: 37–43.
   Google Scholar
• MELTZER HY: Studies of ondansetron in schizophrenia. In: Satellite Symposium (The role of ondansetron, a novel 5-Hr3 receptor antagonist, in the treatment of psychiatric disorders (1991) 5th World Congress of Biological Psychiatry, Florence.
   Google Scholar
• PIPER D, UPTON N, THOMAS D, NICHOLAS J: The effectsof the 5-HT3 receptor antagonists, B1iL43694 andGR38032F, in animal models of anxiety. Br. J. Pharma-col. (1988) 95: 314P.
   Google Scholar
• CRAWLEY JN: Neuropharrnacologic specificity of a sim- ple animal model for the behavioural actions of ben-zodiazepines. Pharmacol. Biochem. Behav. (1981) 15: 695–699.
   PubMed Web of Science ®Google Scholar
• FILE SE, HYDE JRG: Can social interaction be used to measure anxiety? Br. J. Pharmacol. (1978) 62: 19–24.
   Google Scholar
• MONTGOMERY KC: The relation between fear induced by novel stimulation and exploration behaviour. J. Comp. Physiol. Psychol. (1958) 48: 254–260.
   Google Scholar
• BILL DJ, FLETCHER A, GLENN BD, KNIGHT M: Behavioural studies on WAY 100289, a novel 5-HT3 receptor antago-nist, in two animal models of anxiety. Eur.J. Pharmacol. (1992) 218: 327–334.
   PubMed Web of Science ®Google Scholar
• COSTALL B, DOMENEY AM, GERRARD PA, KELLY ME, NAYLOR RJ: Zacopride, anxiolytic profile in rodent and primate models of anxiety. J. Pharm. Pharmacol. (1988) 40: 302–305.
   PubMed Web of Science ®Google Scholar
• JONES BJ, COSTALL B, DOMENEY AM, KELLY ME, NAYLORRJ, OAKLEY NR, TYERS MB: The potential anxiolytic activity of GR38032F, a 5-HT3 receptor antagonist. Br.J. Pharmacol. (1988) 93: 985–993.
   PubMed Web of Science ®Google Scholar
• PIPER DC, KENNEY CA, JENKINS E, BLACKBURN TP, HUGHES HC: A comparison of the anxiolytic activity of BEtL46470A, ondansetron and diazepam in the cyno-molgus monkey. 2nd Int. Symp. on serotonin. (1992) Houston, Abstr p16.
   Google Scholar
• GLENN B, GREEN S: Anxiolytic profile of GR38032F inthe potentiated startle paradigm. Behav. Pharmacol. (1989) 1:91–91.
   PubMedGoogle Scholar
• BLACKBURN TP, BAXTER GS, KENNEll GA, KING FD, PIPER DC, SANGER GJ, THOMAS DR, UPTON N, WOOD MD: BRL46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic prop-erties. Psycopharrn. (1993) 110: 257–264.
   PubMed Web of Science ®Google Scholar
• PECKNOLD JC, LATHE L, INY L, MEANEY M: Platelet [311]-paroxetine and [W]hnipramine binding in zaco-pride treated patients with generalised anxiety disor-der: preliminary results. In: New Concepts in Anxiety (1991). BRILEY M AND FILE S (Eds.), Pierre Fabre Mono-graph Series, MacMillan Press, London pp 168–174.
   Google Scholar
• HAMILTON M: The assessment of anxiety states by rating. Br.J. Med. Psychol. (1959) 32: 50–55.
   PubMed Web of Science ®Google Scholar
• DSMIII.(1980). Diagnostic and Statistical Manual of Men-tal Disorder. The American Psychiatric Association.
   Google Scholar
• LECRUBIER Y, PEUCH AJ, AZCONA A, BAILEY PE, LATASTE X: A randomised double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalised anxiety disorder. Psychopharm. (1993) 112: 129–133,
   PubMed Web of Science ®Google Scholar
• DEROGATIS LR: The SCL-90 manual I: storing, wimini-stration and procedures for the SCL-90. (1977) Clinical Psychometric research, Baltimore, USA.
   Google Scholar
• NATIONAL INSTITUTE OF MENTAL HEALTH. Clinical Global Impression (1976). In: ECDEU assessment manual for psychopharmacology, GUG W. (Ed.), National Institute of Mental Health, Rockville, USA pp217–222.
   Google Scholar
• COSTALL B, JONES BJ, KELLY ME, NAYLOR RJ, ONAIVI ES, TYERS MB: Ondansetron inhibits a behavioural conse- quence of withdrawing from drugs of abuse. Pharrna-col. Biochem. Behav. (1990) 36: 339–344.
   PubMed Web of Science ®Google Scholar
• GOUDIE AJ, LEATHLEY MJ: Effects of the 5-HT3 antago-nist, GR38032F (ondansetron) on benzodiazepine with-drawal lathe rat. Eur.J. Pharmacol. (1990) 185: 179–186.
   PubMed Web of Science ®Google Scholar
• COSTALL B, JONES BJ, KELLY ME, NAYLOR RJ, ONAIVI ES, TYERS MB: Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol. Biochem. Behav. (1990) 36: 97–104.
   PubMed Web of Science ®Google Scholar
• CARBONI E, ACQUAS E, LEONE P, PEREZZANI L, DI CHIARA G: 5-HT3 receptor antagonists block morphine-and nicotine-induced place preference conditioning. Eur J. Pharmacol. (1988) 151: 159–160.
   PubMed Web of Science ®Google Scholar
• KNAPP DJ, POHERECKY LA: Zacopride, a 5-HT3 receptorantagonist, reduces voluntary ethanol consumption in rats. Pharmacol. Biochem. Behav. (1992) 41: 847–850.
   PubMed Web of Science ®Google Scholar
• OAKLEY NR, JONES BJ, TYERS MB, COSTALL B, DOMENEY AM: The effect of GR38032F on alcohol consumption in the marmoset Br. J. Pharmacol. (1988) 95: 870P.
   Google Scholar
• SELLERS EM, KAPLAN HL, LAWRIN MO, SOMER G, NARANJO CA, FRECKER RC: The 5-HT3 antagonist, GR38032F decreases alcohol consumption in rats. Proc. Soc. Neurosci. 18th Ann meet. Toronto, (1988) Abstr. 21.4.
   Google Scholar
• JOHNSON BA, CAMPLING GM, GRIFFITHS P, COWEN PJ: Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psycho-pharmacol, (1993) 112: 142–144.
   PubMed Web of Science ®Google Scholar
• FOZARD JR, GITTOS MW: Selective blockade of 5-hy- s•droxytryptamine neuronal receptors by benzoic acidesters of tropine. Br. J. Pharmacol. (1983) 80: 511P. First report of MDL 72222 as a selective 5-HT3 receptor antagonist.
   Google Scholar
• KING FD, DABBS S, BERMUDEZ J, SANGER GJ: Bensotriaz-inones as "virtual ring" micics of 2-methoxyben-zgmities: novel and potent 5-HT3 receptor antagonists. J. Med. Chem. (1990) 33: 2943–2944.
   Google Scholar
• FOZARD JR: The development and early clinical evalu-ation of selective 5-HT3 receptor antagonists. In: The peripheral actions of 5-hydraxybyptamine (1989). Fozard JR (Ed.), Oxford Medical Publications, Oxford, pp 354–376.
   Google Scholar
• ROBERTSON DW, LACEFIELD WB, BLOOMQUIST W, PFEIFER W, SIMON BL, COHEN ML: Zatosetron, a potent, selective and long acting 5-HT3 receptor antagonist synthesis and structure activity relationships. J. Med. Chem. (1992) 35: 310–319.
   PubMed Web of Science ®Google Scholar
• COHEN ML, BLOOMQUIST W, GIDDA JS, LACEFLELD W: LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity. J. Pharma-col. Exp. Ther. (1990) 254: 350–355.
   PubMed Web of Science ®Google Scholar
• KAWAKITA T, KUROITA T, YASUMOTO M, SANO M, INABA K, FUKUDA T, TAHARA T: Synthesis and pharmacology of 3,4-dihydro-3-oxo-1,4 benzoxazine-8-carboxamide derivatives, a new class of potent serotonin-3 (5-HT3) receptor antagonists. Chem. Pharm. Bull. (1992) 40: 624–630.
   PubMed Web of Science ®Google Scholar
• YOUSSEFYEH RD, CAMPBELL HF, KLEIN S, AIREY DARKES P, POWERS M, SCHNAPPER M, NEUENSCHWAN-DER K, FITZPATRICK LR, PENDLEY CE, MARTIN GE: De-velopment of high affinity 5-HT3 receptor antagonists 1. Initial structure activity relationships of novel ben-zamides. J. Med. Chem, (1992) 35: 895–903.
   Google Scholar
• YOUSSEFYEH RD, CAMPBELL HF, AIREY JE, KLEIN S, SCHNAPPER M, POWERS M, WOOD WARD R, RODRIGUEZ W, GOLEC S, STUDT W, DODSON SA, FITZPATRICK LR, PENDLEY CE, MARTIN GE: Development of high affinity 5-HT3 receptor antagonists 2. Two novel tricyclic ben-zamkles. J. Med. Chem. (1992) 35: 903–911.
   Google Scholar
• LEE CR, PLOSKER GL, MCTAVISH D: Tropisetron: A reviewof its pharmacodynamic and pharmacokinetic proper-ties and therapeutic potential as an anti-emetic. Drugs (1994), 46: 925–943.
   Google Scholar
• GIGER RK, DONATSCH P, ENGER G, RICHARDSON B, STADLER PA: Indo1e-3-carboxylic acid derivatives: a newclass of highly selective and potent antagonists at 5-HT M receptors: Vlllth International Symposium Medicinal Chemistry, Uppsala (1984) 133–135. First report of tropisetron as a selective 5-HT3 receptor antagonist.
   Google Scholar
• BERMUDEZ J, FAKE CS, JOINER GJ, JOINER KA, KING FD, MINER WI), SANGER GJ: 5-hydroxytryptamine (5-HT3) receptor antagonists 1. Indazole and indolizine-3-car-boxylic add Derivatives. J. Med. Chem. (1990) 33: 1924–1929.
   Google Scholar
• PLOSKER GL, GOA KL: Granisetron: a review of its pharmacological properties and therapeutic use as ananti-emetic. Drugs (1992) 42: 805–824. Comprehensive review of granisetron.
   Google Scholar
• FLUDZINSKI P, EVARARD DA, BLOOMQUIST WE, LACE-FIELD WB, PFEIFER W, JONES ND, DEETER JB, COHEN ML: Indazoles as indole bioisosteres: synthesis and evalu-ation of the tropanyl ester and amide of indazole-3-car-boxylate as antagonists at the serotonin 5-HT3 receptor. J. Med. Chem. (1987) 30: 1535–1537.
   PubMed Web of Science ®Google Scholar
• BERMUDEZ J, DABBS S, JOINER KA, KING FD: 5-Hy-droxytryptamine (5-HT3) receptor antagonists 2. 1-In-dolineearboxamides. J. Med. Chem. (1990) 33: 1929–1932.
   Google Scholar
• Z J, DABBS, KING FD: 5-Hydroxytryptamine (5-HT3) receptor antagonists 3. Ortho-substituted phenylureas. J. Med. Chem. (1990) 33: 1932–1935.
   Google Scholar
• BRADLEY G, WARD TJ, WHITE JC, COLEMAN J, TAYLOR A, RHODES KF: Novel antagonists of the 5-HT3 receptor synthesis and structure activity relationships of (2-alit-oxybenzoyl) ureas. J. Med. Chem. (1992) 35: 1515–1520.
   PubMed Web of Science ®Google Scholar
• TURCONI M, NICOLA M, QUINTERO MG, MALOCCHI L, MICHELETTI R, GIRALDO E, DONETTI A: Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzamidazole-1-carboxylic acid derivatives as highly potent 5-ht3 recep-tor antagonists. J. Med. Chem. (1990) 33: 2101–2108.
   PubMed Web of Science ®Google Scholar
• BRITTAIN RT, BUTLER A, COATES IH, FORTUNE DH, HAGAN R, HILL JM, HUMBER A, HUMPHREY PP, HUNTER DC, IRELAND SJ, JACK D, JORDAN CC, OXFORD A, TYERS MB: GR38032F, a novel selective antagonist at 5-ht3 receptors. Br. J. Pharmacol (1987) 90: 87P.
   Google Scholar
• STABLES R, ANDREWS PRL, BAILEY HE, COSTALL B, GUN-NING SJ, HAWTHORN J, NAYLOR RJ, MYERS MB: Anti-emetic properties of the 5-Er3 receptor antagonist GR38032F. Cancer Treatment Rev. (1987) 14: 333–336.
   PubMed Web of Science ®Google Scholar
• MILNE RJ, HEEL RC: Ondansetron - therapeutic use as an anti-emetic. Drugs (1991) 41: 507–664.
   PubMed Web of Science ®Google Scholar
• OXFORD AW, KILPATRICK GJ, TYERS MB: Ondansetro and related 5-HT3 antagonists: recent advances. In:Progress in Medicinal Chemistry (1992). ELLIS GP, LUSCOMBE DK, (Eds.), Elsevier, Amsterdam. 29: 239. Review on Ondansetron.
   Google Scholar
• ROSEN T, NAGEL AA, RIZZI JP, IVES JL, DAFEEN JG, GANONG AD, GUANNO K, HEYM J, MCLEAN S, NOWASK-OWSKI JT, SCHMIDT AW, SEEGER TF, SIOK CJ, VINCENT LA: Thiazole as a carbonyl isostere: a novel class of highly potent and selective 5-HT3 receptor antagonists. J. Med. Chem. (1990) 33: 2715–2720.
   PubMed Web of Science ®Google Scholar
• ROSEN T, NAGEL AA, RIZZI JP: Studies of a novel series of thiarole containing 5-hydroxytryptamine-3-receptor antagonists. In: Drug Design for Neuroscience (1993), KOZ-IKOWSKI AP (Ed.) Raven Press Ltd, New York. p213–230.
   Google Scholar
• ROSEN T, NAGEL AA: CP93318. Drugs of the Future (1991)16: 992–995.
   Google Scholar
• RIZZI JP, NAGEL AA, ROSEN T, MCLEAN S, SEEGER T: AnInitial three component pharmacophore for specific serotonin-3 receptor Uganda. J. Med. Chem. (1990) 33: 2721–2725.
   PubMed Web of Science ®Google Scholar
• SWAIN CJ, BAKER R, KNEEN C, MOSELEY J, SAUNDERS J, SEWARD EM, STEVENSON G, BEER M, STANTON J, WATLING K: Novel 5-HT3 antagonists indole oxadia-zoles. J. Med. Chem. (1991) 34: 140–151.
   PubMed Web of Science ®Google Scholar
• SWAIN CJ, BAKER R, KNEEN C, HERBERT R, MOSELEY J, SAUNDERS J, SEWARD EM, STEVENSON GI, BEER M, STAN-TON J, WATLING K, BALL RG: Novel 5-HT3 antagonists: Indo1-3-y1 spiro(azabicycloalkane-3,5'(4'H)-oxazoles). J. Med. Chem. (1992) 35: 1019–1031.
   PubMed Web of Science ®Google Scholar
• CLIFFE IA, BRAMMER N, MIDDLEFELL V, SWAMINATHANP, WHITE AO: Azaheteroaromatic ethers as carbonyl bioisosteres. Synthesis and evaluation of a novel class of 5-HT3 receptor antagonists. BioMed. Chem. letters (1992) 2: 245–248.
   Google Scholar
• KING FD, HADLEY MS, JOINER KT, MARTIN RT, SANGERGJ, SMITH DM, SMITH GE, SMITH P, TURNER DH: Substi-tuted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z.] derivatives as 5-HT4 recep-tor agonists and gastric motility stimulants. J. Med. Chem. Let. (1993) 36: 683–689.
   Google Scholar
• BERMUDEZ J, GREGORY JA, KING FD, STARR S, SUM-MERSELL RJ: 3-Oxagranatane (3-oxa-9-azabicyclo[3.3.1] nonane). Derivatives as highly potent serotonin 5-HT3 receptor antagonists. BioMed. Chem. Let. (1992) 2: 579–522.
   Google Scholar
• MILLER RC, GALVAN M, GITTOS MW, VANGIERSBERGEN PLM, MOSER PC, FOZARD JR: Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev. Res. (1993) 28: 87–93.
   Web of Science ®Google Scholar
• YOSHIDA N, OMOYA H, KATO S, HO T: 5-HT3 receptor antagonist effects of DAT 582, (R) enantiomer of AS5370. Eur. J. Pharmacol. (1992) 216: 435–440.
   PubMed Web of Science ®Google Scholar
• MIYATA K, KATSUYAMOK Y, KAMATO T, NISHIDO A, HOH, YUKI H, YAMANO M, TSUTSUMI R, TAKEDO M, HONDA K: Antagonism of the serotonin (5-HT3) receptor by YM060, a novel 4,5,6,7-tetrahydrobenzimidazole de-rivative. Jap. J. Pharmacol. (1991) 55 Suppl 1. 364P. References to patent literature
   Google Scholar
• BEECHAM GROUP PLC, US 4959367 (1990)
   Google Scholar
• ELI LILLY AND CO, LEP-307172 (1989)
   Google Scholar
• RORER, US 4859683 (1989)
   Google Scholar
• RORER INTERNATIONAL HOLDINGS W0911688-A (1991)
   Google Scholar
• ELI LILLY AND CO, US4921982 (1990)
   Google Scholar
• ELI LILLY AND CO, US4997950-A (1991)
   Google Scholar
• SYNTEX INC, W09221673-A (1992)
   Google Scholar
• JOHN WYETH AND BROTHER LTD, GB2236757-A (1991)
   Google Scholar
• BEECHAM GROUP PLC, W09117161-A (1991)
   Google Scholar
• ONO PHARM CO LTD, EP-482939 (1992)
   Google Scholar
• YOSHITOMI PHARM, EP-313393 (1989)
   Google Scholar
• YOSHITOMI PHARM, EP-407137 (1991)
   Google Scholar
• SMITHKLINE BEECHAM PLC, W09308186 (1993)
   Google Scholar
• BEECHAM GROUP PLC, EP-200444 (1986)
   Google Scholar
• RORER PHARM CO, EP-350130 (1990)
   Google Scholar
• BEECHAM GROUP PLC, US4937247 (1990)
   Google Scholar
• GD SEARLE & CO, W09215593-A (1992)
   Google Scholar
• BEECHAM GROUP PLC, EP-289170 (1988)
   Google Scholar
• BEECHAM GROUP PLC, EP-287196 (1988)
   Google Scholar
• YAMANOUCHI PHARM CO LTD, EP-376624A (1990)
   Google Scholar
• YAMANOUCHI PHARM CO LTD, EP-381422A (1990)
   Google Scholar
• FERROSAN AS, EP-419397 (1991)
   Google Scholar
• JOHN WYETH AND BROTHER LTD, EP-323077 (1989)
   Google Scholar
• JOHN WYETH AND BROTHER LTD, EP-361629A (1990)
   Google Scholar
• PFIZER INC, EP-397364-A (1990)
   Google Scholar
• PFIZER INC, US4914207-A (1990)
   Google Scholar
• PFIZER INC, US4963689-A (1990)
   Google Scholar
• MERCK SHARP & DOHME LTD, US4940703-A (1990)
   Google Scholar
• MERCK SHARP & DOHME LTD, GB2229182-A (1990)
   Google Scholar
• MERCK SHARP & DOHME LTD, US4952587A (1990)
   Google Scholar
• BEECHAM GROUP PLC, EP-227215 (1988)
   Google Scholar
• BEECHAM GROUP PLC, EP-377967 (1990)
   Google Scholar
• SMITHKLINE BEECHAM PLC, W09308185A (1993)
   Google Scholar
• SMITHKLINE BEECHAM PLC, W09307147A (1993)
   Google Scholar
• MERRELL DOW PHARMACEUTICALS INC, EP-329932 (1989)
   Google Scholar
• DELELANDE, EP-99789 (1984)
   Google Scholar
• BEECHAM GROUP PLC, EP-221702 (1987)
   Google Scholar
• BEECHAM GROUP PLC, US4798829 (1989)
   Google Scholar
• DAINIPPON, EP-358903 (1990)
   Google Scholar
• YAMANOUCHI PHARM, EP-376624 (1990)
   Google Scholar
• YAMANOUCHI PHARM, EP-381422 (1990) Shirley K Rahman, SmithKline Beecham Pharmaceuticals, Coldharbour Rd, The Pinnacles, Harlow, Essex, UK.
   Google Scholar